ADDITIVE CARDIOVASCULAR RISK REDUCTION OF GLP1A AND SGLT2I IN DIABETIC PATIENTS WITH ATHEROSCLEROTIC DISEASE

被引：0
|
作者：
Loyo, Persio Lopez
Bohra, Chandrashekar
Bhatia, Kirtipal
Baruch, Lawrence
Eng, Calvin
机构：
[1] James J Peters VA Med Ctr, New York, NY USA
[2] Mt Sinai Morningside, New York, NY USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2022年 / 79卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1430 / 1430
页数：1
相关论文
共 50 条
  • [1] BENEFITS OF ADDING GLP1A TO SGLT2I THERAPY IN DIABETIC PATIENTS WITH ATHEROSCLEROTIC DISEASE AND HEART FAILURE
    Loyo, Persio Lopez
    Bohra, Chandrashekar
    Bhatia, Kirtipal
    Baruch, Lawrence
    Eng, Calvin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1447 - 1447
  • [2] GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients
    Pablo, Aschner
    Evelyn, Blanc
    Claudia, Folino
    Yanina, Morosan A.
    CURRENT HYPERTENSION REVIEWS, 2021, 17 (02) : 149 - 158
  • [3] USE OF GLP-1 RECEPTOR AGONISTS (GLP1A) AND/OR SGLT-2 INHIBITORS (SGLT2I) IN POPULATIONS WITH NASH OR AT RISK OF NASH IN US CLINICAL PRACTICE
    Lai, Michelle
    Broestl, Jeremy
    Juneja, Kavita
    Milligan, Scott
    Radtchenko, Janna
    Younossi, Zobair M.
    Afdhal, Nezam H.
    GASTROENTEROLOGY, 2020, 158 (06) : S1446 - S1446
  • [4] Use of GLP-1 receptor agonists (GLP1A) and/or SGLT-2 inhibitors (SGLT2I) in populations with NASH or at risk of NASH in US clinical practice
    Lai, Michelle
    Broestl, Jeremy
    Juneja, Kavita
    Milligan, Scott
    Radtchenko, Janna
    Younossi, Zobair
    Afdhal, Nezam
    JOURNAL OF HEPATOLOGY, 2020, 73 : S452 - S452
  • [5] Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction Call for Action to the Cardiology Community
    Nelson, Adam J.
    Pagidipati, Neha J.
    Aroda, Vanita R.
    Cavender, Matthew A.
    Green, Jennifer B.
    Lopes, Renato D.
    Al-Khalidi, Hussein
    Gaynor, Tanya
    Kaltenbach, Lisa A.
    Kirk, Julienne K.
    Lingvay, Ildiko
    Magwire, Melissa L.
    O'Brien, Emily C.
    Pak, Jonathan
    Pop-Busui, Rodica
    Richardson, Caroline R.
    Reed, Monica
    Senyucel, Cagri
    Webb, Laura
    McGuire, Darren K.
    Granger, Christopher B.
    CIRCULATION, 2021, 144 (01) : 74 - 84
  • [6] Cardiovascular outcome with SGLT2i and GLP1RA
    Lim, Soo
    Sohn, Minji
    Nauck, Michael A.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 129 : 133 - 136
  • [7] Predictors of Selection of a GLP1RA vs. SGLT2i in People with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
    Agarwal, Shubham
    Basit, Mujeeb A.
    Bowen, Michael E.
    Heitjan, Daniel
    Mai, Christine
    Marble, Kelsea
    Xiang, Zichang
    Lingvay, Ildiko
    DIABETES, 2024, 73
  • [8] Recent trends in GLP-1 RA and SGLT2i use among people with type 2 diabetes and atherosclerotic cardiovascular disease in the USA
    King, Aaron
    Tan, Xi
    Dhopeshwarkar, Neil
    Bohn, Rhonda
    Dea, Katherine
    Leonard, Charles E.
    de Havenon, Adam
    BMJ OPEN DIABETES RESEARCH & CARE, 2024, 12 (05)
  • [9] Anticipating the Impact of 2019 Guidelines: Use of SGLT2i and GLP-1RA in Patients with Diabetes and Cardiovascular Disease
    Rattelman, Cori R.
    Ciemins, Elizabeth L.
    Cuddeback, John K.
    DIABETES, 2019, 68
  • [10] Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
    Khat, Dorrin Zarrin
    Husain, Mansoor
    CURRENT DIABETES REPORTS, 2018, 18 (07)
12345